Should I buy or sell Aptevo Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aptevo Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" APVO shares. View APVO analyst ratings or view top-rated stocks .

How have APVO shares performed in 2023?

Aptevo Therapeutics' stock was trading at $2.32 on January 1st, 2023. Since then, APVO shares have decreased by 91.4% and is now trading at $0.20. View the best growth stocks for 2023 here .

Are investors shorting Aptevo Therapeutics?

Aptevo Therapeutics saw a drop in short interest during the month of November. As of November 15th, there was short interest totaling 26,900 shares, a drop of 74.2% from the October 31st total of 104,300 shares. Based on an average daily volume of 483,200 shares, the days-to-cover ratio is presently 0.1 days. View Aptevo Therapeutics' Short Interest .

When is Aptevo Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024. View our APVO earnings forecast .

How were Aptevo Therapeutics' earnings last quarter?

Aptevo Therapeutics Inc. (NASDAQ:APVO) posted its quarterly earnings results on Tuesday, November, 14th. The biotechnology company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.64) by $0.14.

What other stocks do shareholders of Aptevo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptevo Therapeutics investors own include Advanced Micro Devices (AMD) , Amarin (AMRN) , AVEO Pharmaceuticals (AVEO) , Alibaba Group (BABA) , Micron Technology (MU) , OPKO Health (OPK) , AbbVie (ABBV) , Aurinia Pharmaceuticals (AUPH) , BioXcel Therapeutics (BTAI) and T2 Biosystems (TTOO) .

Who are Aptevo Therapeutics' major shareholders?

Aptevo Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Sabby Management LLC (11.58%), Armistice Capital LLC (10.72%) and Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends .

How do I buy shares of Aptevo Therapeutics?

Shares of APVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Aptevo Therapeutics Stock Price, News & Analysis (NASDAQ:APVO)

$0.20

+0.01 (+5.32%)

(As of 11:40 AM ET)

Compare

Today's Range: $0.19
▼
$0.20
50-Day Range: $0.18
▼
$0.38
52-Week Range: $0.15
▼
$7.20

Volume: 148,221 shs
Average Volume: 253,138 shs
Market Capitalization: $3.52 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Aptevo Therapeutics MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
0.15% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.96
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.78) to ($1.33) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.80 out of 5 stars

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Aptevo Therapeutics.

5.0

Short Interest

Percentage of Shares Shorted
0.15% of the outstanding shares of Aptevo Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Aptevo Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Aptevo Therapeutics has recently decreased by 74.21%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Aptevo Therapeutics does not currently pay a dividend.
Dividend Growth
Aptevo Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for APVO.

3.3

News and Social Media Coverage

News Sentiment
Aptevo Therapeutics has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Aptevo Therapeutics this week, compared to 0 articles on an average week.
Search Interest
5 people have searched for APVO on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Aptevo Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Aptevo Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.70% of the stock of Aptevo Therapeutics is held by insiders.
Percentage Held by Institutions
Only 8.06% of the stock of Aptevo Therapeutics is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Aptevo Therapeutics are expected to grow in the coming year, from ($1.78) to ($1.33) per share.
Price to Book Value per Share Ratio
Aptevo Therapeutics has a P/B Ratio of 0.07. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Aptevo Therapeutics Stock (NASDAQ:APVO)

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company's lead clinical candidates are APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndromes; and. ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers. Its preclinical candidates include APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40; APVO711, a dual mechanism bispecific ADAPTIR candidate designed to provide synergistic stimulation of CD40 on antigen presenting cells; and APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

APVO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

APVO Stock News Headlines

December 4, 2023 | americanbankingnews.com

Aptevo Therapeutics (NASDAQ:APVO) Now Covered by StockNews.com

November 29, 2023 | americanbankingnews.com

Aptevo Therapeutics Inc. (NASDAQ:APVO) Short Interest Down 74.2% in November

December 4, 2023 | Edge On The Street (Ad)

Is This The Most Overlooked Gold Investment Strategy of 2024?

There is little debate on the potential of gold in the next year and decade. The real issue becomes - what's the best gold investment strategy today? Some investors are opting for a unique "royalty" alternative that outshines other options like holding gold bullion or investing in volatile mining stocks.

November 27, 2023 | americanbankingnews.com

Aptevo Therapeutics (NASDAQ:APVO) Coverage Initiated by Analysts at StockNews.com

November 22, 2023 | msn.com

Aptevo Therapeutics files to sell up to 32.03M shares of common stock for holders

November 14, 2023 | msn.com

Aptevo Therapeutics GAAP EPS of -$0.50

November 14, 2023 | finance.yahoo.com

Aptevo Therapeutics Reports 3Q23 Financial Results and Provides a Business Update

November 1, 2023 | finanznachrichten.de

Aptevo Therapeutics: Aptevo to Present at Bio-Europe Conference

December 4, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 1, 2023 | finance.yahoo.com

Aptevo to Present at Bio-Europe Conference

October 21, 2023 | thestreet.com

With New Cash Aptevo Goes It Alone on Prostate Drug, Shares Up - Biotech Movers

September 26, 2023 | money.usnews.com

Aptevo Therapeutics Inc

August 10, 2023 | finance.yahoo.com

Aptevo Therapeutics Reports 2Q23 Financial Results and Provides a Business Update

August 4, 2023 | finance.yahoo.com

Aptevo Therapeutics Inc. Announces Closing of Previously Announced $5 Million Public Offering

August 3, 2023 | msn.com

Aptevo Therapeutics (APVO) Price Target Increased by 24.14% to 18.36

August 2, 2023 | benzinga.com

Why Aptevo Therapeutics Stock Is Getting Obliterated

August 2, 2023 | investorplace.com

Why Is Aptevo Therapeutics (APVO) Stock Down 33% Today?

August 2, 2023 | msn.com

Aptevo Therapeutics down 25% after pricing $5M offering

August 2, 2023 | finance.yahoo.com

Aptevo Therapeutics Inc. Announces Pricing of $5 Million Public Offering

July 18, 2023 | finanznachrichten.de

Aptevo Therapeutics: Aptevo Announces Positive Duration of Remission Data from Phase 1b Expansion Trial Evaluating the Bispecific APVO436 for AML

July 18, 2023 | benzinga.com

Aptevo Therapeutics Stock Is Sinking Today - Here's Why

June 29, 2023 | ca.finance.yahoo.com

APVO - Aptevo Therapeutics Inc.

May 11, 2023 | finance.yahoo.com

Aptevo Therapeutics Reports 1Q23 Financial Results and Provides Business Update

April 1, 2023 | finance.yahoo.com

Aptevo Therapeutics Full Year 2022 Earnings: EPS Beats Expectations

March 30, 2023 | finance.yahoo.com

Aptevo Therapeutics Raises $9.6 Million in Non-Dilutive Funding

March 30, 2023 | finance.yahoo.com

Aptevo Therapeutics Reports 2022 Financial Results and Provides Business Update

January 9, 2023 | finance.yahoo.com

Aptevo Therapeutics Files Provisional Patent for Fifth Bispecific Antibody APVO711, Intended for the Treatment of Solid Tumors

See More Headlines

Receive APVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptevo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/14/2023
Today: 12/04/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 4/04/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:APVO
CUSIP: N/A
CIK: 1671584
Web: www.aptevotherapeutics.com
Phone: (206) 838-0500
Fax: 206-838-0503
Employees: 45
Year Founded: 2016

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $8.03 million
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -97.61%
Return on Assets: -56.28%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.09
Quick Ratio: 3.09

Sales & Book Value

Annual Sales: $3.11 million
Price / Sales: 1.08
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.84 per share
Price / Book: 0.23

Miscellaneous

Outstanding Shares: 17,620,000
Free Float: 16,965,000
Market Cap: $3.35 million
Optionable: Not Optionable
Beta: 4.94

Social Links

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Mr. Marvin L. White (Age 61)
President, CEO & Director
Comp: $892.86k
Mr. Jeffrey G. Lamothe CA (Age 57)
Executive VP & COO
Comp: $691.37k
Ms. SoYoung Kwon J.D.
LL.M., Senior VP, General Counsel, Business Development & Corporate Affairs
Ms. Daphne L. Taylor (Age 57)
Senior VP & CFO
Dr. Jane A. Gross Ph.D. (Age 66)
Chief Scientific Officer
Comp: $515.17k
Dr. Dirk Huebner M.D. (Age 60)
Chief Medical Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

APVO Stock Analysis - Frequently Asked Questions

Should I buy or sell Aptevo Therapeutics stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aptevo Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" APVO shares.
View APVO analyst ratings or view top-rated stocks.
How have APVO shares performed in 2023?: Aptevo Therapeutics' stock was trading at $2.32 on January 1st, 2023. Since then, APVO shares have decreased by 91.4% and is now trading at $0.20.
View the best growth stocks for 2023 here.
Are investors shorting Aptevo Therapeutics?: Aptevo Therapeutics saw a drop in short interest during the month of November. As of November 15th, there was short interest totaling 26,900 shares, a drop of 74.2% from the October 31st total of 104,300 shares. Based on an average daily volume of 483,200 shares, the days-to-cover ratio is presently 0.1 days.
View Aptevo Therapeutics' Short Interest.
When is Aptevo Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our APVO earnings forecast.

How were Aptevo Therapeutics' earnings last quarter?: Aptevo Therapeutics Inc. (NASDAQ:APVO) posted its quarterly earnings results on Tuesday, November, 14th. The biotechnology company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.64) by $0.14.
What other stocks do shareholders of Aptevo Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Aptevo Therapeutics investors own include Advanced Micro Devices (AMD), Amarin (AMRN), AVEO Pharmaceuticals (AVEO), Alibaba Group (BABA), Micron Technology (MU), OPKO Health (OPK), AbbVie (ABBV), Aurinia Pharmaceuticals (AUPH), BioXcel Therapeutics (BTAI) and T2 Biosystems (TTOO).
Who are Aptevo Therapeutics' major shareholders?: Aptevo Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Sabby Management LLC (11.58%), Armistice Capital LLC (10.72%) and Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends.
How do I buy shares of Aptevo Therapeutics?: Shares of APVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:APVO) was last updated on 12/4/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial